Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alexion Pharmaceuticals    ALXN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2017 10/12/2017 10/13/2017 10/16/2017 10/17/2017 Date
141.23(c) 141.46(c) 140.61(c) 140.84(c) 143.16(c) Last
1 554 534 855 800 721 653 897 415 1 389 505 Volume
-1.81% +0.16% -0.60% +0.16% +1.65% Change
More quotes
Financials ($)
Sales 2017 3 524 M
EBIT 2017 1 472 M
Net income 2017 507 M
Debt 2017 1 294 M
Yield 2017 -
Sales 2018 4 090 M
EBIT 2018 1 929 M
Net income 2018 1 068 M
Finance 2018 289 M
Yield 2018 -
P/E ratio 2017 62,77
P/E ratio 2018 30,28
EV / Sales2017 9,43x
EV / Sales2018 7,74x
Capitalization 31 951 M
More Financials
Company
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.Its products include soliris, strensiq and kanuma.The company was founded... 
Sector
Pharmaceuticals
Calendar
10/26 | 12:30pmEarnings Release
More about the company
Surperformance© ratings of Alexion Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on ALEXION PHARMACEUTICALS
10/14 ALEXION INVESTIGATION INITIATED BY F : Kahn Swick & Foti, LLC Investigates the O..
10/12 ALEXION PHARMACEUTICALS : to Report Third Quarter 2017 Results On Thursday, Octo..
10/10 ALEXION PHARMACEUTICALS : to Report Third Quarter 2017 Results on Thursday, Octo..
10/07 ALEXION INVESTIGATION INITIATED BY F : Kahn Swick & Foti, LLC Investigates the O..
09/30 ALEXION INVESTIGATION INITIATED BY F : Kahn Swick & Foti, LLC Investigates the O..
09/26 ROBBINS ARROYO LLP : Alexion Pharmaceuticals, Inc. (ALXN) Misled Shareholders Ac..
09/19 ALEXION PHARMACEUTICALS : Adds Paul A. Friedman, M.D. To Its Board of Directors
09/19 ALEXION PHARMACEUTICALS : Lupin appoints Jim Loerop to drive M&A, business devel..
09/18 ALEXION PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financi..
09/14 ALEXION PHARMACEUTICALS : Adds Paul A. Friedman, M.D. to Its Board of Directors
More news
Sector news : Biopharmaceuticals
08:52aDJASTRAZENECA : Breast-Cancer Drug Gets Priority Review From FDA
08:48aDJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
08:24a RECKITT BENCKISER : to form two business units for better focus
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17DJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
More sector news : Biopharmaceuticals
Latest Tweets
10/17Alexion Pharma $ALXN buyer of 700 May $165/$200 call spreads for $5.95
4
10/17Public Employees Retirement System of Ohio Increases Stake in Alexion Pharmac.. 
10/17Here Are the Best Looking Revenue Charts (part 3 of 4) - Dr. Fly $REGN $ALXN ..
1
10/1729 Top Stock Ideas For October And Beyond  
10/16Alexion Pharmaceuticals, Inc. $ALXN Position Lowered by Bank of Nova Scotia  
More tweets
Qtime:160
News from SeekingAlpha
10/11 YOUR DAILY PHARMA SCOOP : Alexion's Catalysts, Amgen's Prolia, Ultragenyx Borosu..
10/10 An In-Depth Look At Alexion's Competition And Upcoming Catalysts
10/08 ALEXION : Buy On Dips With Soliris Catalyst Upcoming
10/05 YOUR DAILY PHARMA SCOOP : The First Trust NYSE Arca Biotechnology Index, Gilead'..
10/02 YOUR DAILY PHARMA SCOOP : Alexion's Canada Pricing, Zogenix, RedHill, Flexion
Chart ALEXION PHARMACEUTICALS
Duration : Period :
Alexion Pharmaceuticals Technical Analysis Chart | ALXN | US0153511094 | 4-Traders
Technical analysis trends ALEXION PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 163 $
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Ludwig N. Hantson Chief Executive Officer & Director
David Richard Brennan Chairman
Julie O'Neill Executive Vice President-Global Operations
Paul J. Clancy Chief Financial Officer
John J. Orloff Executive VP & Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ALEXION PHARMACEUTICALS14.92%31 951
BIOGEN28.45%70 973
CSL LIMITED37.10%49 302
GRIFOLS SA27.81%17 727
BIOMARIN PHARMACEUTICAL14.82%16 591
CHONGQING ZHIFEI BIOLOGICAL PRDCT CO LTD--.--%6 705